New insights into SUMOylation and NEDDylation in fibrosis DOI Creative Commons
Han Jin, Jun Wu,

Wen-Tao Kou

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 4, 2024

Fibrosis is the outcome of any abnormal tissue repair process that results in normal replacement with scar tissue, leading to persistent damage and cellular injury. During fibrosis, many cytokines chemokines are involved, their activities controlled by post-translational modifications, especially SUMOylation NEDDylation. Both these modifications entail a three-step activation, conjugation, ligation involves three kinds enzymes, namely, E1 activating, E2 conjugating, E3 ligase enzymes. participates organ fibrosis modulating FXR, PML, TGF-β receptor I, Sirt3, HIF-1α, Sirt1, while NEDDylation influences regulating cullin3, NIK, SRSF3, UBE2M. Further investigations exhibit therapeutic potentials SUMOylation/NEDDylation activators inhibitors against ginkgolic acid MLN4924 These demonstrate effects highlight as well potential candidates. In future, deeper needed identify novel substrates fibrosis; moreover, clinical determine can benefit patients. This review highlights function targets for fibrosis.

Language: Английский

Exploring potential targets for natural product therapy of DN: the role of SUMOylation DOI Creative Commons
Jingjing Wang, Rui Zhang,

Chenguang Wu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Oct. 4, 2024

Diabetic nephropathy (DN) is a common and serious micro-vascular complication of diabetes leading cause end-stage renal disease globally. This primarily affects middle-aged elderly individuals, especially those with history over 10 years poor long-term blood glucose control. Small ubiquitin-related modifiers (SUMOs) are group reversible post-translational modifications proteins that widely expressed in eukaryotes. SUMO intervene the progression DN by modulating various signaling cascades, such as Nrf2-mediated oxidative stress, NF-κB, TGF-β, MAPK pathways. Recent advancements indicate natural products regulating SUMOylation hold promise targets for intervening DN. In previous article published 2022, we reviewed mechanisms which intervenes fibrosis presented summary some therapeutic potential. Therefore, this paper will focus on The aim review to elucidate mechanism action related potential, thereby summarising candidate treatment through modulation SUMOylation, ginkgolic acid, ginkgolide B, resveratrol, astragaloside IV, etc., highlighting product-mediated potential strategy strategy.

Language: Английский

Citations

0
SENP7 inhibits glioblastoma metastasis and invasion by dissociating SUMO2/3 binding to specific target proteins DOI Creative Commons
Jixing Zhang,

Hongshan Zheng,

Liang Peng

et al.

Open Medicine, Journal Year: 2024, Volume and Issue: 19(1)

Published: Jan. 1, 2024

The poor surgical efficacy and recurrence of glioblastoma (GBM) are due to its lack visible infiltrative features. Our bioinformatics study suggests that low expression small ubiquitin-like modifier (SUMO)-specific protease 7 (SENP7) indicates prognosis in GBM.

Language: Английский

Citations

0
Dysregulated gene expression of SUMO machinery components induces the resistance to anti-PD-1 immunotherapy in lung cancer by upregulating the death of peripheral blood lymphocytes DOI Creative Commons
Ying Wang,

Chao Sun,

Mengmeng Liu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 15, 2024

Background The majority of patients with lung cancer exhibit drug resistance after anti-PD-1 immunotherapy, leading to shortened patient survival time. Previous studies have suggested an association between epigenetic abnormalities such as methylation and clinical response while the role SUMOylation in antibody immunotherapy is still unclear. Methods Here, mRNA expression 15 SUMO machinery components PBMC from receiving were analyzed using real-time PCR. Base on percentage change levels, relationship outcomes influencing factors evaluated. was treated different concentrations 2-D08 (a specific inhibitor SUMOylation) vitro , activation death rates lymphocyte subsets by flow cytometry analysis. Results A predictive method, base gene three ( SUMO1 SUMO3 UBE2I ), developed distinguish non-responders PD-1 inhibitors. Furthermore, number lymphocytes peripheral blood significantly reduced dysregulated groups (the >100 or -50 ~ -100 groups). In confirmed that lightly low level improved status T NK lymphocytes, but extremely lead increased lymphocytes. Conclusion Our findings implied could induce upregulating These data might provide effective circulating biomarkers for predicting efficacy uncovered a novel regulatory mechanism immunotherapy.

Language: Английский

Citations

0
New insights into SUMOylation and NEDDylation in fibrosis DOI Creative Commons
Han Jin, Jun Wu,

Wen-Tao Kou

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Dec. 4, 2024

Fibrosis is the outcome of any abnormal tissue repair process that results in normal replacement with scar tissue, leading to persistent damage and cellular injury. During fibrosis, many cytokines chemokines are involved, their activities controlled by post-translational modifications, especially SUMOylation NEDDylation. Both these modifications entail a three-step activation, conjugation, ligation involves three kinds enzymes, namely, E1 activating, E2 conjugating, E3 ligase enzymes. participates organ fibrosis modulating FXR, PML, TGF-β receptor I, Sirt3, HIF-1α, Sirt1, while NEDDylation influences regulating cullin3, NIK, SRSF3, UBE2M. Further investigations exhibit therapeutic potentials SUMOylation/NEDDylation activators inhibitors against ginkgolic acid MLN4924 These demonstrate effects highlight as well potential candidates. In future, deeper needed identify novel substrates fibrosis; moreover, clinical determine can benefit patients. This review highlights function targets for fibrosis.

Language: Английский

Citations

0